AstraZeneca stuns everyone by pulling its Covid-19 vaccine worldwide amid concerns and low demand.
AstraZeneca, the Anglo-Swedish pharmaceutical giant, has made a monumental decision to withdraw its Oxford-collaborated Covid-19 vaccine, Vaxzevria, from global markets. This move comes as the company faces a decline in demand and acknowledges the potential risks associated with the vaccine, including the rare side effect of TTS (Thrombosis with Thrombocytopenia Syndrome). A total of twenty-three cases of blood clots were reported in individuals who received the AstraZeneca vaccination, seven of which were confirmed to be linked to the vaccine.
The withdrawal of the Covid-19 vaccine by AstraZeneca has sent shockwaves through the medical community. With the availability of new vaccines and a surplus of updated options, the company decided to pull back its once highly successful vaccine. This decision has raised questions about the future of 'monovalent' vaccines and the evolving dynamics of global vaccination strategies.
While AstraZeneca's move to withdraw its Covid-19 vaccine globally is a significant development, the Serum Institute of India, a major vaccine manufacturer, has not indicated any plans for withdrawal. This divergence in actions highlights the complexities of vaccine regulation and distribution across different regions. The withdrawal also underscores the importance of ongoing monitoring and evaluation of vaccine safety and effectiveness.
In a surprising turn of events, AstraZeneca attributed the withdrawal of its Covid-19 vaccine to 'commercial reasons.' This statement has sparked discussions about the intersection of public health and business interests in the pharmaceutical industry. As the world continues to navigate the challenges of the pandemic, the decisions made by companies like AstraZeneca have far-reaching implications for global health policies and vaccine deployment strategies.
AstraZeneca is withdrawing its Oxford-collaborated Covid-19 vaccine from global markets, the UK-based pharma company confirmed in a statement to Endpoints ...
Anglo-Swedish drugmaker AstraZeneca on Wednesday said it was withdrawing Covid vaccine Vaxzevria, one of the first produced in the deadly pandemic, ...
AstraZeneca had recently admitted in court documents that its vaccine against Covid-19 has the potential to cause TTS, a rare side effect associated with ...
Twenty-three people in the country were reported to have experienced blood clots after receiving the AstraZeneca vaccination, with seven confirmed to have been ...
(RTTNews) - AstraZeneca, a major provider of Covid-19 vaccines across the world mainly during the initial pandemic period, has initiated a process to ...
LONDON: British drugmaker AstraZeneca said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, ...
Global pharma giant AstraZeneca has decided to withdraw its Covid-19 vaccine worldwide after the company admitted in court documents that it can have ...
AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in ...
While the Serum Institute of India has not yet made any statements of withdrawal, experts say that eventually, all 'monovalent' vaccines, or those that deal ...
AstraZeneca has begun the global withdrawal of its Covid-19 vaccine Vaxzevria, citing a surplus of updated vaccines.
AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its Covid-19 vaccine due to a "surplus of available updated vaccines" since the ...
The pharmaceutical giant announced the withdrawal of it vaccine, Vaxzevria, due to a surplus.
In India, Covishield is manufactured by the Serum Institute of India (SII) under a licensing agreement with AstraZeneca. SII, one of the world's leading ...
AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a "surplus of available updated vaccines" since the ...
It said the rise of new coronavirus variants meant demand had shifted to the newer updated vaccines. Its vaccine was estimated to have saved millions of lives ...
LONDON -- The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator ...
The withdrawal is due to a “surplus of available updated vaccines” since the pandemic. Read more at straitstimes.com.
The vaccine, initially approved in January 2021, faced safety concerns over rare blood clots, prompting various countries to halt its use temporarily.
Anglo-Swedish drugmaker says availability of newer vaccines hit demand for jab.
The development follows the launch of a class action suit in the UK over allegations that the UK vaccine caused blood clots in a large number of covid-19 ...
Pharmaceutical giant AstraZeneca announced the global withdrawal of its COVID-19 vaccine, Vaxzevria. The company attributed the decision to an abundance of ...
The Oxford-AstraZeneca vaccine was a critical part of the COVID-19 pandemic response. However, on May 7 2024, the European Commission announced the vaccine ...
The drugmaker is pulling the shot from all markets, ending a turbulent saga that saw it successfully develop a coronavirus shot but struggle to sell it.
Pharmaceutical giant AstraZeneca on Wednesday said it planned to withdraw its Covid-19 vaccine as demand for it has declined.
The European Medicines Agency has accepted a request from AstraZeneca to withdraw the marketing authorization for its COVID-19 shot Vaxzevria.
Alex Reid was wrongly advised on early vaccination due to a clinical mistake 17 years earlier.
The pharmaceutical giant announced the withdrawal of it vaccine, Vaxzevria, due to a surplus.
The company said its decision was due to an 'overabundance of updated vaccines' on the market, and a 'decline in demand' for its vaccine Vaxzevria.
“Global demand for all COVID vaccines is now much lower and overall supply exceeds demand. This is in marked contrast to the early part of the pandemic when ...